Bright Minds Biosciences Inc.
DRUG Nasdaq
SEC CIK 1827401
Follow Bright Minds Biosciences
Weekly email: filings, results
Net income
−CAD 2.8M
+62% vs prior year
EPS, diluted
−CAD 0.65
+67.2% vs prior year
Operating cash flow
−CAD 1.9M
+73.7% vs prior year
Source: SEC XBRL filings · latest filing
Show the numbers
| Year | Net income |
|---|---|
| FY24 | −CAD 2.8M |
| FY23 | −CAD 7.4M |
| FY22 | −CAD 15M |
| FY21 | −CAD 8.7M |
| FY20 | −CAD 480.4K |
| FY19 | - |
| FY18 | - |